LXX.CN - Lexaria Bioscience Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
1.8000
-0.1400 (-7.22%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.9400
Open1.9600
Bid1.78 x 0
Ask1.79 x 0
Day's Range1.8000 - 1.9600
52 Week Range1.0000 - 3.1300
Volume84,146
Avg. Volume108,175
Market Cap140.64M
Beta (3Y Monthly)4.94
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE16 hours ago

    Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria's DehydraTECH(TM) Powered TurboCBD(TM) Capsules

    KELOWNA, BC / ACCESSWIRE / February 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBD™, the Company's proprietary, DehydraTECH™ powered, cannabidiol (''CBD'') fortified hemp-oil capsule.

  • GlobeNewswire21 days ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Gaining Appeal in Cannabis Edibles with DehydraTECH

    NEW YORK, Feb. 01, 2019 -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Outside Investment, New Technology Support Growing Cannabis.

  • GlobeNewswire22 days ago

    CannabisNewsWire Announces Publication on Cannabis Industry Innovations and Advancements Drawing Investment from Big Corporations

    NEW YORK, Jan. 31, 2019 -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • GlobeNewswirelast month

    NetworkNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp.’s Proprietary Technology Levels Field with Big Players in Bioscience

    NEW YORK, Jan. 23, 2019 -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Definitive Agreement Marks Milestone for Alternative Nicotine.

  • GlobeNewswirelast month

    NetworkNewsWire Announces Publication on Innovators at the Door of Big Tobacco in Quest for Cigarette Alternatives

    NEW YORK, Jan. 17, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.

  • GlobeNewswirelast month

    Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology

    KELOWNA, British Columbia, Jan. 17, 2019 -- via NetworkWire -- Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), has entered.

  • CNW Grouplast month

    IIROC Trade Resumption - LXX

    VANCOUVER , Jan. 15, 2019 /CNW/ - Trading resumes in: Company: Lexaria Bioscience Corp. CSE Symbol: LXX Resumption (ET): 12:00 PM IIROC can make a decision to impose a temporary suspension (halt) of trading ...

  • ACCESSWIRElast month

    Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH(TM) Technology for Oral Nicotine

    Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement. The Altria investment will fund research on regulatory compliant, oral forms of nicotine ...

  • CNW Grouplast month

    IIROC Trading Halt - LXX

    VANCOUVER , Jan. 15, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Lexaria Bioscience Corp. CSE Symbol: LXX Reason: At the request of the Company Pending News Halt Time (ET): 8:36 ...

  • GlobeNewswirelast month

    Exclusive Interview: Lexaria CEO Discusses Progress & Plans at O’Cannabiz 2018 -- CFN Media

    SEATTLE, Jan. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE:LXX) (CN) (CNSX:LXX) (LXRP). The company is a developer of drug delivery technologies for bioactive compounds, Lexaria is one of the oldest companies in the cannabis industry.

  • GlobeNewswire3 months ago

    CannabisNewsWire Announces Growing Cannabis Acceptance Setting Stage For Consumable Cannabis Boom

    NEW YORK, Nov. 29, 2018 -- via CannabisNewsWire -- CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer

    KELOWNA, BC / ACCESSWIRE / November 26, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has submitted a Health Canada research application, and appointed Dr. Ed Ergenzinger to its executive team. The Company has submitted its research application under Health Canada's Cannabis Tracking and Licensing System for the operation of a Kelowna-based R&D laboratory within Lexaria's new head office under construction, to work with cannabinoids. The laboratory will enhance Lexaria's ability to formulate for analytical purposes, various products that may contain cannabinoids or other controlled substances.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Launches ChrgD+

    KELOWNA, BC / ACCESSWIRE / November 13, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder packet formulation designed to be added to any drink, in any location, creating many innovative-use applications. Consistent with other Lexaria formulations, ChrgD+ incorporates multi-spectrum hemp oil processed using the Company's patented DehydraTECHTM technology, allowing effective delivery of hemp oil into any existing beverage, hot or cold. "This new delivery format is truly unique in its performance," said Chris Bunka, CEO of Lexaria Bioscience.

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Announces Increased Size and Closing of Private Placement

    KELOWNA, BC / ACCESSWIRE / October 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that due to strong demand it has increased the size of its previously announced non-brokered private placement, closing on gross proceeds of US$1,515,440 (the "Offering"). Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to acquire one common share of the Company at a price of US$2.25 per common share for a period of 24 months following the closing of the Offering.

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Receives Two New Granted Patents

    KELOWNA, BC / ACCESSWIRE / October 18, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has been granted two new US patents. Lexaria now has six granted patents in the US and four granted patents in Australia. All ten of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Creates and Brands Subsidiary Companies

    KELOWNA, BC / ACCESSWIRE / October 10, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has completed the creation of four wholly-owned subsidiary companies. This new corporate structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. The subsidiaries are each empowered with Lexaria's patented DehydraTECHTM technology.

  • ACCESSWIRE5 months ago

    Lexaria Files New Patent Application for Delivery of Tobacco-Derived Products

    KELOWNA, BC / ACCESSWIRE / September 28, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the filing of a new strategic patent application. The new provisional patent application is entitled "Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof". This application represents Lexaria's tenth patent family and expands the applicability of the already-patented DehydraTECHTM technological process to impart benefits to tobacco leaves that may be utilized to deliver compounds that may or may not include nicotine.

  • ACCESSWIRE6 months ago

    Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance

    KELOWNA, BC / ACCESSWIRE / September 7, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company"or "Lexaria"), a drug delivery platform innovator, announces strategic additions to its patent portfolio. Three new Australian patents were granted to Lexaria by the Australian Patent Office, bringing the Company's worldwide patent portfolio to eight issued patents: four each in the US and Australia.